 GenMark Diagnostics, Inc. GNMK, a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary financial and operational results for the quarter ended June 30, 2020. The GenMark team continued to deliver excellent progress throughout the second quarter, said Scott Mendel, President and Chief Executive Officer. 